{
    "clinical_study": {
        "@rank": "168277", 
        "arm_group": [
            {
                "arm_group_label": "PAC-14028 cream 1%", 
                "arm_group_type": "Experimental", 
                "description": "PAC-14028 cream 1%, twice daily for 8 weeks"
            }, 
            {
                "arm_group_label": "Rozex gel 0.75%", 
                "arm_group_type": "Active Comparator", 
                "description": "Rozex gel 0.75%, twice daily for 8 weeks"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle, twice daily for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of\n      Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea"
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Erythematotelangiectatic Rosacea", 
            "Papulopustular Rosacea"
        ], 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients at the age of 20 to 65 years old\n\n          -  Clinical diagnosis of erythematotelangiectatic or papulopustular rosacea according to\n             National Rosacea Committee Expert Society with\n\n               -  Erythema severity \u2265 1\n\n               -  Telangiectasia severity \u2265 1\n\n               -  At least 3 papules or pustules in facial region\n\n          -  IGA score \u2265 2\n\n          -  Voluntarily signed written informed consent forms for study participation\n\n        Exclusion Criteria:\n\n          -  Patients who are unable to be diagnosed or evaluated for rosacea due to tattoo or\n             scar in the facial area\n\n          -  Patients who are unable to be diagnosed or evaluated for rosacea due to excess\n             hair(e.g., mustache, beard, whiskers etc.) in the facial area\n\n          -  Patients who are sensitive to the drug or vehicle\n\n          -  Previous administration of oral retinoid or vitamin A(\u226510,000 units/day) within 6\n             months prior to visit 1\n\n          -  Previous use of estrogen or oral contraceptives within 3 months prior to visit 1\n\n          -  Previous use of topical retinoids or oral antibiotics (e.g., tetracycline,\n             tetracycline derivatives, erythromycin, erythromycin derivatives, sulfamethoxazole,\n             trimethoprim) or oral steroid for the treatment of facial rosacea within 1 month\n             prior to visit 1\n\n          -  Previous use of topical steroid or topical antibiotics, topical treatment for\n             rosacea(e.g., metronidazole, azelaic acid) within 2 weeks prior to visit 1\n\n          -  Presently undergoing anti-coagulant therapies\n\n          -  History of hematologic disease\n\n          -  Ocular-only, Phymatous rosacea, or papulopustular rosacea patients who require\n             systemic antibiotics\n\n          -  History of laser treatment for rosacea within 6 weeks prior to visit 1\n\n          -  Alcoholic or drug abuse patients\n\n          -  Patients who are treated with prohibited concomitant drugs or considered to\n             inevitably require treatment with prohibited concomitant drugs during the study\n             period\n\n          -  Renal function impairment with creatinine level higher than twice of maximum normal\n             range\n\n          -  Hepatic function impairment with AST/ALT higher than twice of maximum normal range\n\n          -  Pregnant and lactating woman, woman with child-birth potential(should have negative\n             pregnancy test at the baseline visit of the study)\n\n          -  Participation in another clinical study within 1 month prior to screening\n\n          -  Patients considered ineligible for study participation by the principal investigator\n             or sub-investigator for other reasons; rosacea due to other medical (liver disease,\n             renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052999", 
            "org_study_id": "TRPV1-ROSACEA_IIT"
        }, 
        "intervention": [
            {
                "arm_group_label": "PAC-14028 cream 1%", 
                "description": "Participants received topical PAC-14028 cream 1% twice daily for 8 weeks", 
                "intervention_name": "PAC-14028 cream 1%", 
                "intervention_type": "Drug", 
                "other_name": "PAC-14028"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Participants received topical Vehicle twice daily for 8 weeks", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Other", 
                "other_name": "Vehicle of PAC-14028 Cream"
            }, 
            {
                "arm_group_label": "Rozex gel 0.75%", 
                "description": "Participants received topical Rozex gel 0.75% twice daily for 8 weeks", 
                "intervention_name": "Rozex gel 0.75%", 
                "intervention_type": "Drug", 
                "other_name": "Rozex gel 0.75%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metronidazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Chung-Ang University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open Label Pilot Study to Evaluate the Efficacy of PAC-14028 in the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea", 
        "overall_official": {
            "affiliation": "Department of Dermatology, Chungang University Hospital", 
            "last_name": "BeomJoon Kim, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "-", 
            "measure": "Change in Investigator Global Assessment (IGA)", 
            "safety_issue": "No", 
            "time_frame": "Baseline through Study Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "-", 
                "measure": "Erythema severity", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Week 8"
            }, 
            {
                "description": "-", 
                "measure": "Telangiectasia severity", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Week 8"
            }, 
            {
                "description": "-", 
                "measure": "Inflammatory lesion counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Week 8"
            }
        ], 
        "source": "Amorepacific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amorepacific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}